"Treatment-resistant" sounds like a conclusion. In clinical use it's closer to a bookmark. The working definition most researchers share is the failure of two adequate trials of antidepressants drawn from different medication classes, which means the label describes a treatment history, not a person who can't get better.
That distinction matters because of what prescribers do next. The label isn't the end of a decision tree. It's the point where a careful clinician stops asking "which drug now" and starts asking whether the picture they've been working from was ever complete.
Before the Label Sticks, the Prescriber Audits the Record
The first move isn't a new prescription. It's a look back at what actually happened during the trials that supposedly failed. Clinicians are advised to rule out what's called pseudo-resistance, and up to half of apparent nonresponse may trace to poor adherence or poor tolerability rather than a drug that simply didn't work. That's a very different problem with a very different fix.
Judging whether a past trial was adequate means confirming four concrete things: that the dosage was titrated appropriately, that the drug was given long enough at that dose, that adherence was actually monitored, and that someone recorded whether the response was partial or complete. Partial response, in particular, tends to get filed as failure when it's really information. A drug that moved the needle halfway is telling you something about direction.
Reading the clinical commentary closely, our editors keep landing on the same point: narrowing the field of remaining medications is part of widening the picture, not a shortcut around it. That commentary describes a shift away from prescribing based on what helps the average patient toward personalized approaches that use genetic analysis or other testing to help predict how an individual might respond to a specific antidepressant, with early research centered on variation in the CYP450 enzyme system, particularly CYP2D6. Medications on the GeneSight Psychotropic report are one external example of the documentation a prescriber may be reading at this stage. Information of that kind narrows the field of candidates rather than identifying a drug that will work, and it doesn't replace the diagnostic rethink.
Six Weeks, Three Weeks, and the Argument Over Both
An antidepressant trial only counts against a patient if it met real thresholds. A monotherapy trial is considered adequate once it has run at least six weeks at a minimum effective dose, while an augmentation or combination trial added within that same initial trial is considered adequate at three weeks. Those are the numbers doing the work behind the word "adequate," and they're why a prescriber will ask how long you stayed on something and at what dose before treating it as a dead option.
Plenty of real-world trials don't clear the bar. A month at a starting dose that was never increased isn't a failed trial. Neither is six weeks of a medication you stopped taking in week three because the side effects were intolerable. Those are incomplete experiments, and clinicians who count them as evidence of resistance are building a case on thin material.
The thresholds themselves are also softer than they look. Clinicians acknowledge that the six-week and three-week benchmarks are expert convention rather than settled fact, and some researchers would prefer a longer threshold, such as 12 weeks. If the field can't agree on when a trial has had a fair run, that's a reason for humility about any individual verdict. Living inside that uncertainty for months is grueling, and it's one reason medication decisions tend to go better alongside ongoing talk therapy; readers looking for background on that side of treatment can find the clinic's depression counseling page.
Comorbidity Explains a Lot of Apparent Resistance
A depression that won't move sometimes isn't just depression. In the STAR*D study, 35% of depressed patients had at least one additional diagnosable psychiatric disorder, comorbid anxiety disorders ranged from 12% for agoraphobia to 31% for social anxiety, and 53% of patients qualified as having anxious depression. More than half. That's not an edge case, it's the typical presentation.
Anxious depression behaves differently in treatment, which is part of why it matters whether anyone named it. A reader who recognizes that overlap in their own history may want the clinic's anxiety counseling page alongside this one.
Substance use is the other common complication. Almost 30% of patients with major depression in STAR*D also had co-occurring alcohol or drug misuse. An antidepressant competing against active drinking isn't getting a fair test, and no amount of switching classes will change that arithmetic.
Then there's diagnostic overlap, where symptoms get attributed to the wrong condition entirely. Leading studies estimate that the prevalence of comorbid depressive disorders among children with ADHD ranges from 9% to 38%. That's a wide band, and the width is the point: the relationship between attention problems and mood is messy enough that an unrecognized co-occurring condition can sit underneath a depression picture for years. Someone whose concentration never recovered, whose motivation looks like anhedonia, whose task paralysis reads as depressive inertia, might be getting treated for one thing while another goes unaddressed.
What STAR*D Found at Step One
At the first treatment step, using citalopram, 32.9% of participants achieved remission.
That figure reframes what a first failed trial means. It wasn't a badly designed study or a poorly chosen drug. It was a reasonable first-line medication given properly, and most participants still needed something beyond it. Within the field's own working definition, resistance requires two adequate trials from different medication classes, which means one disappointing round doesn't even reach the threshold people fear being labeled with.
So when a prescriber responds to a stalled trial by reviewing adherence, checking dose and duration, re-screening for anxiety or substance use, reconsidering the diagnosis, and looking at what information exists about the medications still on the table, that isn't stalling. It's the sequence the evidence calls for. A first-step remission rate of 32.9% is the plainest argument available that the step after the first one is where most of the work happens.